MaineHealth
This is a single institution, single surgeon, randomized controlled trial to evaluate the Boston Scientific Lumenis Pulse 120H Moses 2.0 holmium laser versus the Olympus Soltive Superpulsed thulium fiber laser (TFL) for medium-to-large stones in the mini PCNL setting.
Multiple procedural modalities for treating nephrolithiasis are available to patients with the ultimate choice dependent on stone size, location, and patient factors. For over 30 years, the holmium: yttrium-aluminum-garnet (Ho:YAG) laser has been the gold standard for laser lithotripsy due to its efficiency in stone fragmentation irrespective of stone composition and its enviable safety profile. Different energies, pulse rates, pulse durations, and work settings are utilized based on stone density and surgeon intent for fragmentation versus dusting. Basic physical principles underlie the effe…
Inclusion Criteria: * Scheduled to undergo mini PCNL for nephrolithiasis * Stone burden (multiple stones acceptable) with largest stone 1cm - 3 cm in greatest dimension on bone window of noncontrast CT within a 6 month preoperative period. * Able to give informed consent * Age 21 or older Exclusion Criteria: * Patients scheduled to undergo concurrent non-PCNL procedure such as contralateral ureteroscopy * Inability to give informed consent * Age less than 21 * Body Mass Index (BMI) \>45 * Pregnant or breastfeeding patients * Stone burden outside of inclusion criteria range * Untreated urina…
Assigned to be treated using the Lumenis Pulse 120H Moses 2.0 Holmium Laser.
Assigned to be treated using the Olympus Soltive Thulium SuperPulsed Fiber Laser
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.